99 related articles for article (PubMed ID: 10511060)
1. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.
Mould DR; Davis CB; Minthorn EA; Kwok DC; Elliott MJ; Luggen ME; Totoritis MC
Clin Pharmacol Ther; 1999 Sep; 66(3):246-57. PubMed ID: 10511060
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.
Hepburn TW; Totoritis MC; Davis CB
Rheumatology (Oxford); 2003 Jan; 42(1):54-61. PubMed ID: 12509613
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.
Sharma A; Davis CB; Tobia LA; Kwok DC; Tucci MG; Gore ER; Herzyk DJ; Hart TK
J Pharmacol Exp Ther; 2000 Apr; 293(1):33-41. PubMed ID: 10734150
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.
Yocum DE; Solinger AM; Tesser J; Gluck O; Cornett M; O'Sullivan F; Nordensson K; Dallaire B; Shen CD; Lipani J
J Rheumatol; 1998 Jul; 25(7):1257-62. PubMed ID: 9676753
[TBL] [Abstract][Full Text] [Related]
5. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
Mason U; Aldrich J; Breedveld F; Davis CB; Elliott M; Jackson M; Jorgensen C; Keystone E; Levy R; Tesser J; Totoritis M; Truneh A; Weisman M; Wiesenhutter C; Yocum D; Zhu J
J Rheumatol; 2002 Feb; 29(2):220-9. PubMed ID: 11838838
[TBL] [Abstract][Full Text] [Related]
6. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.
van der Lubbe PA; Breedveld FC; Tak PP; Schantz A; Woody J; Miltenburg AM
J Autoimmun; 1997 Feb; 10(1):87-97. PubMed ID: 9080303
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
8. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
[TBL] [Abstract][Full Text] [Related]
10. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
11. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
Ng CM; Bruno R; Combs D; Davies B
J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
[TBL] [Abstract][Full Text] [Related]
13. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
14. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
15. Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis.
Garfield BE; Krahl T; Appel S; Cooper SM; Rincón M
Clin Immunol; 2005 Aug; 116(2):101-7. PubMed ID: 15914087
[TBL] [Abstract][Full Text] [Related]
16. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes.
Ellingsen T; Hornung N; Møller BK; Hjelm-Poulsen J; Stengaard-Pedersen K
Scand J Immunol; 2007 Oct; 66(4):451-7. PubMed ID: 17850590
[TBL] [Abstract][Full Text] [Related]
17. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
Skov L; Kragballe K; Zachariae C; Obitz ER; Holm EA; Jemec GB; Sølvsten H; Ibsen HH; Knudsen L; Jensen P; Petersen JH; Menné T; Baadsgaard O
Arch Dermatol; 2003 Nov; 139(11):1433-9. PubMed ID: 14623703
[TBL] [Abstract][Full Text] [Related]
18. Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.
Moreland LW; Haverty TP; Wacholtz MC; Knowles RW; Bucy RP; Heck LW; Koopman WJ
J Rheumatol; 1998 Feb; 25(2):221-8. PubMed ID: 9489810
[TBL] [Abstract][Full Text] [Related]
19. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
[TBL] [Abstract][Full Text] [Related]
20. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.
Maurice MM; van der Graaff WL; Leow A; Breedveld FC; van Lier RA; Verweij CL
Arthritis Rheum; 1999 Oct; 42(10):2166-73. PubMed ID: 10524689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
